Skip to content
Research/Metabolic Optimization/Tralesinidase Alfa

Tralesinidase Alfa

Tralesinidase alfa is an enzyme replacement therapy designed to treat metabolic disorders by supplementing deficient or malfunctioning enzymes. Its primary mechanism involves restoring normal metabolic function, which can help manage symptoms and improve quality of life in affected individuals. This compound is relevant for longevity and health optimization as it addresses underlying metabolic dysfunctions that can lead to chronic health issues.

Intelligence Profile

Safety Profile

Safety Profile of Tralesinidase Alfa

Known Side Effects
Evidence from a phase I/II study (PMID: 36413418) suggests that tralesinidase alfa, administered via intracerebroventricular infusion, is associated with certain side effects. Reported side effects in patients with Sanfilippo syndrome type B include:

  • Infusion-related reactions: These can manifest as mild to moderate headaches, fever, vomiting, or nausea.
  • Central nervous system effects: Some patients experienced mild confusion or dizziness following administration.

Animal studies in juvenile cynomolgus monkeys (PMID: 36923444) support these findings, with similar side effects observed, emphasizing the potential for infusion-related reactions.

Contraindications
The current literature does not provide specific contraindications for tralesinidase alfa. However, caution is advised in patients with known hypersensitivity to the drug components. Further specific contraindications may become clearer as more data from clinical trials become available.

Drug Interactions
There is limited information available on the drug interactions of tralesinidase alfa. As new studies are conducted, additional evidence may highlight potential interactions. For now, healthcare providers should carefully consider the drug profiles of concurrent medications typically administered to patients with Sanfilippo syndrome type B.

Populations to Avoid
Given the data from clinical trials and animal studies, certain populations may need to exercise caution:

  • Pregnant or Breastfeeding Women: There is insufficient evidence on the effects of tralesinidase alfa in pregnant or breastfeeding populations. Until more data is available, it is advisable to avoid use unless absolutely necessary.
  • Patients with Severe Allergic Histories: Due to the risk of infusion-related reactions, patients with a history of severe allergies should be monitored closely if treatment is considered.

Conclusion

The safety profile of tralesinidase alfa, specifically for its use in patients with Mucopolysaccharidosis Type IIIB, is still emerging. Current evidence highlights some side effects primarily associated with the infusion process. Ongoing clinical trials, like the phase 3 study (NCT07579910), will potentially provide more comprehensive data on safety, helping to better define contraindications, drug interactions, and populations needing special consideration.

Disclaimer: This summary is for informational purposes only. It is not a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider regarding any medical condition or treatment decisions.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.